Undulating Balloon Systems and Methods for Nanoparticle-Based Drug Delivery
Systems and methods for localized drug delivery via undulating drug coated balloons (DCB), in particular using functionalized nanoparticles as a drug delivery medium in combination with an undulating balloon, are disclosed. In various disclosed embodiments, a nanoparticle matrix is adhered to in an external substrate-surface, such as the balloon surface, and is activated for release once at the treatment site. Activation for release may be enhanced through the use of an undulating balloon system including methodologies for precise control of timing, waveform and extent of undulations.
1 . An undulating balloon PTA system, comprising:
a balloon catheter comprising an inflatable balloon member having a preset maximum inflation pressure;
an oscillating fluid pressure source communicating with the balloon catheter;
a controller configured to cause the oscillating fluid pressure source to deliver controlled pressure oscillations to the balloon catheter between a maximum pressure equal to the preset maximum inflation pressure and a set minimum pressure at a selected cycle time; and
a drug carrying nanoparticle matrix disposed on an outer surface of the balloon member.
2 . The undulating balloon PTA system of claim 1 , wherein the set minimum pressure is not more than 50% less than the maximum pressure.
3 . The undulating balloon PTA system of claim 2 , wherein the controller is further configured to deliver the pressure oscillations at a cycle time of 10 seconds to about 0.25 seconds.
4 . (canceled)
5 . (canceled)
6 . (canceled)
7 . (canceled)
8 . The undulating balloon PTA system of claim 1 , wherein the oscillating fluid pressure source comprises a drive motor operatively controlled by the controller.
9 . The undulating balloon PTA system of claim 8 , wherein the oscillating fluid pressure source further comprises a syringe body with a plunger driven by the drive motor.
10 . (canceled)
11 . The undulating balloon PTA system of claim 1 , wherein:
said balloon catheter includes a balloon member comprising a double balloon with a first inner balloon and a second outer balloon;
said oscillating fluid pressure source communicates with the outer balloon through a first inflation lumen in the balloon catheter; and
a non-oscillating pressure source communicates with the inner balloon through a second inflation lumen in the balloon catheter.
12 . The undulating balloon PTA system claim 1 , wherein:
said balloon catheter includes a segmented balloon member comprising plural balloon segments, being independently inflatable via separate inflation lumens in the balloon catheter; and
at least one said oscillating fluid pressure source communicates with said balloon segments through said inflation lumens.
13 . The undulating balloon PTA system of claim 12 , wherein:
the system further comprises plural said oscillating fluid pressure sources; and
each balloon segment inflation lumen communicates with a different said oscillating fluid pressure source, whereby each balloon segment is provided with separately controllable fluid pressure oscillations.
14 . (canceled)
15 . The undulating balloon PTA system of claim 1 , wherein the drug-carrying nanoparticle matrix contains microchannels, whereby blood may circulate in the microchannels to increase hydration of the nanoparticle matrix.
16 . The undulating balloon PTA system of claim 1 , wherein:
the nanoparticle matrix comprises drug-carrying nanoparticles and interstitial bonding agent; and
the interstitial bonding agent is configured to release the drug-carrying nanoparticles in response to predetermined stimulus or conditions.
17 . The undulating balloon PTA system of claim 16 , wherein the predetermined condition is a predetermined time in contact with blood within a vessel to be treated.
18 . The undulating balloon PTA system of claim 16 , wherein the stimulus is temperature or pH.
19 . The undulating balloon PTA system of claim 16 , wherein:
the stimulus is thermal energy, sonic energy or light energy; and
the balloon catheter further comprises a transducer disposed within the balloon member configured to generate the corresponding stimulus energy.
20 . The undulating balloon PTA system of claim 16 , wherein the stimulus is sonic energy and the system further comprises an external ultrasound transducer configured to deliver sonic energy at a frequency under 1 MHz.
21 . The undulating balloon PTA system of claim 16 , wherein;
the interstitial bonding agent comprises conductive particles; and
the balloon member includes at least one conductive element, whereby electrical current delivered through the at least one conductive element releases the drug-carrying nanoparticles.
22 . The undulating balloon PTA system of claim 21 , wherein the at least one conductive element comprises a plurality of conductive filaments on an outer surface of the balloon member.
23 . (canceled)
24 . (canceled)
25 . (canceled)
26 . (canceled)
27 . (canceled)
28 . A method of treating vascular disease, comprising:
placing a balloon across a lesion in a vessel, the balloon having an outer surface with a nanoparticle matrix disposed thereon, the nanoparticle matrix including drug-carrying nanoparticles;
inflating the balloon using an inflation fluid to a selected maximum pressure;
delivering controlled pressure oscillations to the balloon through the inflation fluid, the controlled pressure oscillations oscillating between the selected maximum pressure and a set minimum pressure, said oscillations provided at a selected cycle time; and
releasing the drug-carrying nanoparticles from the nanoparticle matrix during said delivering, whereby said pressure oscillations facilitate ingress of the drug-carrying nanoparticles into the lesion and surrounding tissue.
29 . The method of treatment of claim 28 , wherein:
the drug-carrying nanoparticle matrix contains microchannels; and
said releasing comprises allowing blood to circulate in the microchannels to increase hydration of the nanoparticle matrix.
30 . The method of treatment of claim 28 , wherein the nanoparticle matrix comprises an interstitial bonding agent configured to release the drug-carrying nanoparticles in response to predetermined stimulus or condition.
31 . The method of treatment of claim 30 , wherein the predetermined condition is a predetermined time in contact with blood within a vessel to be treated and said releasing comprises maintaining the balloon across the lesion for a time at or exceeding the predetermined time.
32 . The method of treatment of claim 30 , wherein the stimulus is temperature or pH.
33 . The method of treatment of claim 30 , wherein the stimulus is thermal energy and said releasing comprises directing heat energy at the nanoparticle matrix.
34 . The method of treatment of claim 30 , wherein the stimulus is sonic energy and said releasing comprises directing sonic energy at the nanoparticle matrix.
35 . The method of treatment of claim 30 , wherein the stimulus is light energy and said releasing comprises directing light energy at the nanoparticle matrix.
36 . The method of treatment of any of claims 30 , wherein said predetermined stimulus comprises directing an energy source at the nanoparticle matrix from a transducer disposed within the balloon member.
37 . The method of treatment of claim 36 , wherein said directing of the energy -source comprises directing said energy at a level selected to disrupt the interstitial bonding agent while minimizing or avoiding triggering proliferation of smooth muscles cells in the vessel wall or thickening of the intimal layer.
38 . The method of treatment of claim 30 , wherein the interstitial bonding agent comprises a material sensitive to temperature and said releasing comprises introducing the balloon member into the vessel causing a change in property of the interstitial bonding agent, whereby drug-carrying nanoparticles are released from the balloon member surface.
39 . The method of treatment of claim 30 , wherein the interstitial bonding agent comprises a material sensitive to pH and said releasing comprises introducing the balloon member into the vessel causing a change in property of the interstitial bonding agent, whereby drug-carrying nanoparticles are released from the balloon member surface.
40 . The method of treatment of claim 30 , wherein the interstitial bonding agent comprises conductive particles and said releasing comprises delivering a current to the balloon member surface to free the drug-carrying nanoparticles from the nanoparticle matrix.
41 . (canceled)
42 . An undulating balloon PTA system, comprising:
a balloon catheter including at least one balloon having a preset maximum inflation pressure;
a manually actuatable fluid pressure source communicating with the balloon catheter and comprising a syringe body and plunger received in the syringe body;
an oscillating fluid pressure source communicating with the balloon catheter, wherein manually actuatable fluid pressure source and the oscillating fluid pressure source comprise a common syringe body and plunger and actuation of the plunger is switchable between manual actuation and motor driven actuation;
a drive motor powering the oscillating pressure source; and
a controller configured to control the drive motor to cause the oscillating pressure source to deliver controlled pressure oscillations to the balloon catheter, said control comprising -
delivering fluid pressure oscillations between a maximum pressure equal to the preset maximum inflation pressure and a set minimum pressure not more than 50% less than the maximum pressure;
delivering the fluid pressure oscillations at a selected cycle time in the range of about 10 seconds to about 0.25 seconds; and
a drug-carrying nanoparticle matrix disposed on an outer surface of the balloon, the nanoparticle matrix comprising drug-carrying nanoparticles and interstitial bonding agent, wherein the interstitial bonding agent is configured to release the drug-carrying nanoparticles in response to predetermined timulus or conditions, wherein the drug-carrying nanoparticle matrix contains microchannels, whereby blood may circulate in the microchannels to the increase hydration of the nanoparticle matrix.
43 - 67 . (canceled)